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Abstract
Cyclin K, a newly recognized member of the ‘‘tran-
scription’’ cyclin family, may play a dual role by
regulating CDK and transcription. Using cDNA micro-
array technology, we found that cyclin K mRNA was
dramatically increased in U373MG, a glioblastoma cell
line deficient in wild- type p53, in the presence of
exogenous p53. An electrophoretic mobility -shift assay
showed that a potential p53-binding site (p53BS) in
intron 1 of the cyclin K gene could indeed bind to p53
protein. Moreover, a heterologous reporter assay re-
vealed that the p53BS possessed p53-dependent tran-
scriptional activity. Colony-formation assays indicated
that overexpression of cyclin K suppressed growth of
T98G, U373MG and SW480 cells. The results suggested
that cyclin Kmay play a role in regulating the cell cycle or
apoptosis after being targeted for transcription by p53.
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Introduction
The tumor suppressor gene p53 encodes a transcription
factor that binds to specific DNA sequences and activates
transcription of its target genes [1]. Numerous p53 targets
have already been discovered by our group and others. Of
those, p21/WAF1 and BAX are believed to be the most
important because they mediate two major functions of p53,
cell cycle arrest and apoptosis, respectively [2-4]. Given
that hundreds of possible p53-binding sequences may be
present in the human genome [5], we assume that the
tumor-suppressive role of p53 probably reflects physiolog-
ical activities of numerous and widely diverse target genes.
Hence, identification of additional p53 targets may contin-
ually yield clues to the pathways involved in tumorigenesis
and clarify mechanisms that protect cells from a variety of
cellular stresses.
Cyclin K was first identified in a yeast screen based on its
ability to restore cell cycle progression and rescue Saccha-
romyces cerevisiae cells from lethality resulting from deletion
of G1 cyclin [6 ]. Cyclin K was also isolated in a two-hybrid
screen using human CDK9 as bait, and biochemical analysis
confirmed that cyclin K can activate CDK9 activity by forming
a stable protein complex with CDK9 [7]. The CDK9–cyclin K
complex phosphorylates the carboxyl - terminal domain
(CTD) of RNA polymerase II (RNAPII ), a reaction that is
considered to be one of the most important steps in
transcription of many genes [8]. However, the function of
cyclin K remains to be elucidated in detail.
Until now, our efforts to isolate p53- target genes have
involved two different methods. One method was differential
display, using a cell line in which expression of an
exogenous wild- type p53 gene can be regulated under the
control of the lactose operon [9]. In this manner we isolated
five novel p53 targets, TP53TG1 [9 ]; TP53TG3 [10];
fractalkine, which is a chemokine regulating migration and
targeting cytotoxic T cell and NK cell [11]; p53R2, which is
commonly involved in p53-dependent DNA repair in
response to diverse agents of DNA damage [12]; and
p53DINP1, which mediates the p53-dependent apoptotic
pathway [13]. The other method was a yeast enhancer–
trap system that allowed direct cloning of functional p53-
binding sequences from human genomic DNA [5]. By
isolating and sequencing cosmid clones containing every
p53-binding site (p53BS) obtained in that way, we identified
four novel p53- target genes in the genomic regions
surrounding the binding sequences: GML [14], P2XM
[15], BAI1 [16] and p53AIP1 [17]. GML contributes to the
sensitivity of cells to anticancer drugs; BAI1 inhibits angio-
genesis in gliomas, and the p53AIP1 product is a pivotal
mediator of p53- induced apoptosis.
As a third approach to isolation of additional p53- target
genes we have been applying cDNA-microarray technology.
That effort has yielded evidence that cyclin K is yet another
direct transcriptional target of p53.
Materials and Methods
Cell Lines
Human cancer cell lines U373MG (glioblastoma), and
SW480 (colon carcinoma) cells were purchased from the
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American Type Culture Collection (Manassas, VA). T98G
(glioblastoma) was purchased from the Human Science
Research Resource Bank (Tokyo, Japan). All cells were
cultured under conditions recommended by their respective
depositors.
Construction and Infection of Recombinant Adenovirus
Replication-deficient recombinant viruses Ad-p53 and
Ad-LacZ, containing wild- type p53 and LacZ genes,
respectively, were generated and purified as described
previously [17]. U373MG cells were infected by the viral
solutions at a multiplicity of infection of 80 and incubated at
378C until the time of harvest.
RNA preparation
Total RNAs were isolated from transfected cells with
Trizol reagent (Life Technologies, Rockville, MD) following
the manufacturer’s instructions, on a time course of 0, 6, 12,
24, and 48 hours after infection. Poly(A)+ RNAs were
purified with mRNA purification kits (Amersham Pharmacia
Biotech, Uppsala, Sweden).
cDNA Microarray
The cDNA microarray was fabricated essentially as
described elsewhere [18] In brief, we amplified human
cDNAs, including ESTs of interest, based on sequences in
the UniGene database (National Center for Biotechnology
Information, Bethesda, MD) using gene-specific sets of
oligonucleotide primers. 9216 independent PCR products
ranging in size from 0.2 to 1 kb were purified and robotically
spotted onto type 7 glass slides (Amersham Pharmacia
Biotech) by means of the Microarray Spotter Generation III
(Amersham). Aliquots of poly(A)+ RNA (1 g) were reverse
transcribed and second-strand synthesis was performed.
Double-stranded cDNAs were then amplified once with the
Ampliscribe T7 Transcription Kit (Epicentre Technologies,
Madison, WI). Finally, 2.5-g aliquots of amplified RNA from
U373MGcells infectedwith Ad-LacZ or Ad-p53were labeled
with Cy3 or Cy5, respectively, using a cDNA synthesis
system (Life Technologies). Arrays were hybridized with
equal amounts of Cy3- and Cy5- labeled DNA probes, then
washed and scanned by the ArrayScanner according to the
supplier’s protocol (Amersham Pharmacia Biotech). Signal
intensities of Cy3 and Cy5 from individual spots were
quantified and analyzed by substituting backgrounds using
ArrayVision software ( Imaging Research, Ontario, Canada).
Northern Blot Hybridization
A 2-g aliquot of each poly(A)+ RNA was separated by
electrophoresis on a 1% agarose gel containing 6% formalin
and transferred onto a nylon membrane. Membranes blotted
with poly(A)+ RNA from various human tissues were
purchased from Clontech, Palo Alto, CA. Prehybridization
and hybridization were carried out in solutions containing
50% formamide, 5 Denhardt’s solution, 6 SSC, and 1%
salmon sperm DNA. The probe, a 344-bp cDNA fragment
carrying coding sequences of cyclin K, was labeled with
[32P]dCTP using a random primer labeling kit (Megaprime,
Amersham Pharmacia Biotech) according to the manufac-
turer’s instructions. The blots were hybridized with the
radioactive probes at 428C for 16 hours, washed with 0.1
SSC/0.1%SDS at 558C, and exposed to Kodak X-Omat
films (Eastman Kodak, Rochester, NY) at 808C for 24
hours (cyclin K ) or 1 hour ( -actin ).
cDNA Library Screening
We constructed a cDNA library using poly(A)+ RNA
obtained from U373MG cells infected with Ad-p53 for 48
hours and screened 1106 independent colonies of this
library with the same probe that was used for Northern
blotting.
Electrophoretic Mobility -Shift Assay (EMSA)
Oligonucleotides representing the candidate sequence
(p53BS) were synthesized and annealed (p53BS sense,
50 -AAACTAGCTTGCAGACATGCTG-30; p53BS antisense,
50 -CAGCATGTCTGCAAGCTAGTTT-30 ). Nuclear extracts
from H1299 cells infected with Ad-p53 were incubated for
30 minutes at RT with 2.0 g of sonicated salmon sperm
DNA, EMSA buffer (0.5 TBE, 20 mM HEPES (pH 7.5),
0.1 M NaCl, 1.5 mM MgCl2, 10 mM DTT, 20% glycerol,
0.1% NP-40, 1 mM PMSF, 10 mg/ml pepstatin, 10 mg/ml
leupeptin), the [33P]ATP- labeled double-strand oligomer,
and, in some cases, with monoclonal anti -p53 antibodies
PAb421 (Oncogene Science, Cambridge, MA) and/or
PAb1801 (Santa Cruz Biotechnology, Santa Cruz, CA).
After incubation, the samples were electrophoresed in
native 4% polyacrylamide gels using 0.5 TBE. The gels
were dried and exposed for autoradiography at 808C for
3 hours.
Heterologous-Reporter Assay
Heterologous-reporter vectors designed to possess the
500-bp segment corresponding to intron 1 of the cyclin K
gene were constructed to contain the p53BS ( intron 1-wt).
Using specifically designed oligonucleotides (sense, 50 -AA-
AACGCGTCTGGCTTGACAAAAGTGGTTC-30; antisense,
50 -AAACTCGAGTAGCGACTCTTTAACTTCTAC-30 ), the
segment was generated by PCR and ligated between the
MluI and XhoI sites of the pGL3-promoter vector (Promega,
Madison, WI). Then two nucleotide-exchanged mutations
( the 4th and 16th nucleotides of p53BS) were inserted
( intron 1-mt). In brief, the QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) was used twice,
according to the manufacturer’s instructions, using two sets
of oligonucleotides: mt (4th) BS sense, 50 -GATAAGAA-
AACTATCTTGCAGACATGCTG-30 and mt (4th) BS anti-
sense, 50 -CAGCATGTCTGCAAGATAGTTTTCTTATC-30
and mt (16th) BS sense, 50 -GCTTGCAGACATTCTG-
CAACGCAGCAGAC-30, and mt (16th) BS antisense, 50 -
GTCTGCTGCGTTGCAGAATGTCTGCAAGC-30. The con-
structs of all plasmids were confirmed by sequencing.
H1299 cells were plated in six-well culture plates
(1105 cells ) 24 hours before cotransfection of 1 g of
pGL3-BS, pGL3-mtBS, or pGL3-promoter vector with
wild- type or mutant- type p53 expression vectors (wt -p53
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or mt-p53) in combination with 1 g of pRL-TK vector
(Promega), using 6 l of FuGENE 6 transfection reagent
according to the manufacturer’s optimized methodology
(Roche, Basel, Switzerland). Forty eight hours after
transfection, the cells were lysed in 500 l of a passive
lysis buffer (Promega). Cell lysates were forwarded
directly to the luciferase assay. The dual luciferase
system (Promega) was applied for the sequential meas-
urement of firefly and Renilla luciferase activities with
specific substrates of beetle luciferin and coelenterazine,
respectively. Quantification of both luciferase activities and
calculation of relative ratios were carried out manually with
a luminometer.
Construction of Expression Vectors (pcDNA-cyclin K-S and
pcDNA-cyclin K-AS)
Plasmids (pcDNA-cyclin K-S) designed to express cyclin
K were constructed by cloning the entire coding region of
cyclin K cDNA into the pcDNA3.1( + ) expression vector
( Invitrogen, San Diego, CA), which carries a CMV promoter
and a gene conferring neomycin resistance. The same
fragment was inserted into the pcDNA3.1( ) vector for
construction of the antisense expression vector as a control
(pcDNA-cyclin K-AS). The constructs were confirmed by
sequencing.
Colony-Formation Assay
T98G, U373MG, and SW480 cells (5105 each) were
plated in 10-cm culture dishes 24 hours before trans-
fection. Eight micrograms of expression vector (pcDNA-
cyclin K-S or pcDNA-cyclin K-AS) were transfected using
24 l of FuGENE 6 transfection reagent (Roche); 48 hours
later the harvested cells were diluted and replated on 10-
cm dishes. The transfected cells were allowed to grow in
the presence of 0.8 mg/ml of G-418 (geneticin, Life
Technologies) for 2 weeks, after which the colonies formed
from each cell were fixed with 10% formaldehyde, stained
with crystal violet, and counted.
Figure 1. Transcriptional activation of cyclin K by p53 and a potential p53BS in the cyclin K gene. (A ) Northern blot analysis of cyclin K mRNA expression in the
U373MG glioblastoma cell line at the indicated times after infection with either Adp53 or AdLacZ. Hybridization of the same blot with a  -Actin probe quantifies the
amount of mRNA loaded in each lane. (B ) Genomic structure and a p53BS of cyclin K. The cyclin K gene consists of 11 exons that span a 35 - kb genomic region, and
a potential p53 BS was found in intron 1 (arrow ). The consensus sequence for p53 binding is indicated as (R )=purine, (Y )=pyrimidine, and (W)=A or T. Of the 20
base pairs of p53BS (with a two -base spacer ), 19 match the consensus sequence.
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Results
To identify additional genes that are transcriptional targets
of p53, we applied cDNA-microarray technology using as
probes cDNAs reverse transcribed from mRNAs of p53-
deficient U373MG cells infected by either Ad-p53 or Ad-
LacZ. Duplicate microarrays containing 9216 human cDNAs
were hybridized with a mixture of Cy5- labeled cDNA probes
corresponding to Adp53- infected cells and Cy3- labeled
cDNA probes corresponding to AdLacZ- infected cells.
Dozens of genes showed increased signal intensities of
Cy5, in a time-dependent manner. Among them, one EST
(UniGene accession number Hs.12186) revealed striking
induction by p53. To clone the full - length cDNA of this
gene, we constructed a cDNA library using poly(A)+ RNA
Figure 2. Cyclin K as a direct target of p53. (A ) EMSA. Anti - p53 antibodies Pab421 and Pab1801 were present in the lanes designated ‘‘ + ’’. Interaction between
p53 protein and DNA was inhibited by unlabeled oligonucleotides corresponding to the binding site of the cyclin K gene ( competitor DNA [self ] ), but not by
nonspecific oligonucleotides ( competitor DNA [nonspecific ] ). (B ) Luciferase assay. 500 -bp fragments corresponding to intron 1 of the cyclin K gene, containing the
possible p53 -binding sequence without or with point mutations, were cloned into Luciferase reporter vector (wt -BS or mt -BS ). These two vectors were
cotransfected into H1299 cells along with wt - p53, mt -p53 (R175H or C277R ), or pcDNA3.1 vector (mock ). Luciferase activity was indicated relative to the activity
of reporter vector without the p53 -binding sequence.
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obtained from U373MG cells infected with Ad-p53, and
screened 106 independent colonies of the cDNA library
using a 400-bp DNA fragment of the EST as a probe. As a
result, 20 independent clones were isolated and sequenced.
A BLAST search of the public database indicated that DNA
sequences of this gene were identical to parts of cyclin K
(GenBank accession number AF060515). Comparison of
the cDNA with genomic DNA (GenBank accession number
AL110504) indicated that the archived cDNA sequence
lacked the first exon. Northern blot analysis showed that the
2.8-kb mRNA of cyclin K was rapidly induced in U373MG
after infection with Ad-p53 (Figure 1A ). Multi - tissue
Northern blots revealed ubiquitous expression of cyclin K
(data not shown).
To determine whether cyclin K is a direct target of p53, we
searched for a p53-binding sequence(s) within its 35-kb
genomic sequence (AL110504). A potential p53-binding
sequence (p53BS) was found in intron 1. Nineteen of the
20 nucleotides of this p53BS matched the consensus
p53-binding sequence proposed by el -Deiry et al. [19]
(Figure 1B ).
We performed an EMSA using a nuclear extract purified
from H1299 cells infected by Ad-p53, after synthesizing
oligonucleotides corresponding to the p53BS. As shown in
Figure 2A, this sequence bound to a protein contained in the
nuclear extract ( lane 1), and the band was super-shifted in
the presence of mouse monoclonal anti -p53 antibody
Pab421, indicating that p53BS bound to the p53 protein
( lane 2). This evidence was further clarified by specific
competition with self -DNA but not with nonspecific DNA
( lanes 3 and 4), and also by the fact the band was super-
super-shifted by addition of another mouse monoclonal
anti -p53 antibody, Pab1801 ( lane 5).
To examine p53-dependent transcriptional activity of
p53BS, we performed a heterologous reporter assay using a
plasmid containing 500-bp fragments encompassing p53BS
or p53mtBS ( intron 1-wt or intron 1-mt) in intron 1 of the
cyclin K gene. As shown in Figure 2B, luciferase activity of
pGL3-BS ( intron 1-wt) was enhanced more than 10- fold by
cotransfection with wt-p53 vector than by cotransfection with
either mt-p53 vector or mock vector. Moreover, the mutated
sequence ( intron 1-mt) apparently inhibited the wild- type
p53-dependent enhancement of luciferase activity. Taken
together, these results indicated that cyclin K is a direct
target for p53.
We further examined whether endogenous p53 could
induce cyclin K expression in response to cellular stresses
causing DNA damage, such as gamma irradiation, adriamy-
cin treatment, and UV irradiation. As shown in Figure 3, the
expression of cyclin K was induced by three different
stresses in MCF7 p53+ / + cells. However, the expression
was not induced at all by any stress in H1299 p53 / cells
(Figure 3 ). The result indicated that cyclin K is transcription-
ally activated in response to diverse cellular stresses in a
p53-dependent manner.
To test whether cyclin K might regulate the cell cycle or
apoptosis, we performed colony- formation assays. T98G
and U373MG glioblastoma cell lines and SW480 colorectal
cancer cell line were transfected with pcDNA-cyclin K-S
(sense), pcDNA-cyclin K-AS (antisense) or pcDNA3.1
Figure 3. Induction of endogenous cyclin K mRNA by DNA damages by 1.0 g /ml adriamycin ( top ), 50 Gy gamma radiation (middle ), or 10 J /m2 UV radiation
(bottom) in MCF7 cells ( p53+ / + ) and H1299 cells ( p53 /  ). Expressions of p21WAF1 and  - actin were used as a positive control and a quantity control,
respectively, in Northern blot to examine cyclin K expression at the indicated times after exposure to diverse genotoxins.
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(mock). Transfected cells were allowed to grow in medium
containing G-418; colonies formed by each cell line were
fixed, stained, and counted 2 weeks later. In all three cancer
cell lines, overexpression of sense-cyclin K (cyclin K-S)
caused the suppression of cell growth (Figure 4 ). Especially
in T98G and U373MG cells, a reduction of more than 50% in
colony numbers was observed when cells had been trans-
fected with sense-cyclin K (cyclin K-S) compared to cells
transfected with antisense-cyclin K (cyclin K-AS) and mock
vector (Figure 4 ). The results suggested that cyclin K might
play a role in suppression of cell growth after being targeted
for transcription by p53.
Discussion
Cell cycle regulation and apoptosis are the most important
features for p53’s tumor suppression. In fact, overproduction
of exogenous p53 in cancer cells causes the remarkable
growth suppression through induction of cell cycle arrest or
apoptosis. These functions are mediated by several p53-
target genes. p21WAF1 and 14-3-3 are pivotal mediators for
cell cycle arrests at G1 and G2 phases, respectively. BAX
and p53AIP1 mediate p53-dependent apoptosis. In addition,
cyclin G was reported to be a direct target of p53, which
might be involved in cell cycle regulation or apoptosis
[21,22]. However, except for its sequence similarity to other
cyclins, there is no evidence that it regulates cell cycle. In this
study, we demonstrated that cyclin K is the second known
example, the first being cyclin G, of cyclin genes as a p53
target. Moreover, we showed that ectopic expression of
cyclin K induced the growth suppression in several cancer
cell lines. Although the mechanism for cyclin K–dependent
growth control remains to be elucidated, our results clearly
suggest its involvement in cell cycle regulation or apoptosis.
Cyclin K was recently identified in a genetic screen in
yeast by virtue of its ability to complement the lethality
associated with the deletion of G1 cyclin genes [6]. It can
form a stable protein complex with CDK9; in published
experiments the specific activity of the CDK9–cyclin K
complex was 10 to 15 times greater than that of CDK9 alone
[7]. This complex phosphorylates the CTD of RNAPII and
functionally substitutes for positive transcription factor b
(P-TEFb), comprised of CDK9 and cyclin T, to regulate
transcription in vitro [20]. Phosphorylation of the CTD of
RNAPII is an important step in transcription, and P-TEFb
may facilitate elongation at many genes [8]. Our results and
these observations prompt us to speculate that p53 might
regulate transcription of many genes indirectly, by activating
expression of cyclin K.
Taken together, we propose a model that cyclin K might
regulate the transcription of some cell cycle regulators or
apoptosis- related factors through phosphorylation of CTD of
RNAPII, resulting in cell cycle arrests or apoptosis. Discov-
ery of cyclin K as a p53 target, which is involved in
transcriptional regulation of multiple genes, could also
provide a reason why p53 can amplify and boost its
physiological functions efficiently.
References
[1] Levine AJ (1997). p53, the cellular gatekeeper for growth and division.
Cell 88, 323–31.
[2] el -Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R,
Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993).
WAF1, a potential mediator of p53 tumor suppression. Cell 75,
817–25.
[3] Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ (1993).
The p21 cdk - interacting protein cip1 is a potent inhibitor of G1 cyclin -
dependent kinases. Cell 75, 805–16.
[4] Miyashita T, and Reed JC (1995). Tumor suppressor p53 is a direct
transcriptional activator of the human bax gene. Cell 80, 293–99.
[5] Tokino T, Thiagalingam S, el -Deiry WS, Waldman T, Kinzler KW, and
Vogelstein B (1994). p53 tagged sites from human genomic DNA. Hum
Mol Genet 3, 1537–42.
[6] Edwards MC, Wong C, and Elledge SJ (1998). Human cyclin K, a novel
RNA polymerase II –associated cyclin possessing both carboxy -
terminal domain kinase and Cdk -activating kinase activity. Mol Cell
Biol 18, 4291–4300.
[7] Fu TJ, Peng J, Lee G, Price DH, and Flores O (1999). Cyclin K
functions as a CDK9 regulatory subunit and participates in RNA
polymerase II transcription. J Biol Chem 274, 34527–30.
Figure 4. Colony - formation assay. Numbers of G -418 resistant colonies grown from each of two glioblastoma cell lines (T98G and U373MG) and one colorectal
cancer cell line (SW480 ) transfected with pcDNA-cyclin K -S ( sense ), pcDNA-cyclin K -AS (antisense ) or pcDNA3.1 (mock ). The experiments were repeated at
least three times using triplicate samples, and the average scores are shown with error bar.
Neoplasia . Vol. 4, No. 3, 2002
Cyclin K Is a Target for p53 Mori et al. 273
[8] Napolitano G, Majello B, Licciardo P, Giordano A, and Lania L (2000).
Transcriptional activity of positive transcription elongation factor b
kinase in vivo requires the C - terminal domain of RNA polymerase II.
Gene 254, 139–45.
[9] Takei Y, Ishikawa S, Tokino T, Muto T, and Nakamura Y (1998).
Isolation of a novel TP53 target gene from a colon cancer cell line
carrying a highly regulated wild - type TP 53 expression system. Genes
Chromosomes Cancer 23, 1–9.
[10] Ng CC, Koyama K, Okamura S, Kondoh H, Takei Y, and Nakamura Y
(1999). Isolation and characterization of a novel TP53 - inducible gene,
TP53TG3. Genes Chromosomes Cancer 26, 329–35.
[11] Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C,
Ogawa M, Nakamura Y, and Arakawa H (2000). Identification of
fractalkine, a CX3C - type chemokine, as a direct target of p53. Cancer
Res 60, 3722–26.
[12] Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K,
Takei Y, and Nakamura Y (2000). A ribonucleotide reductase gene
involved in a p53 -dependent cell - cycle check point for DNA damage.
Nature 404, 42–49.
[13] Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y,
Monden M, and Nakamura Y (2001). p53DINP1, a p53 - inducible gene,
regulates p53 -dependent apoptosis. Mol Cell 8, 85–94.
[14] Furuhata T, Tokino T, Urano T, and Nakamura Y (1996). Isolation of a
novel GPI -anchored gene specifically regulated by p53; correlation
between its expression and anti - cancer drug sensitivity. Oncogene 13,
1965–70.
[15] Urano T, Nishimori H, Han H, Furuhata T, Kimura Y, Nakamura Y, and
Tokino T (1997). Cloning of P2XM, a novel human P2X receptor gene
regulated by p53. Cancer Res 57, 3281–87.
[16] Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K,
Yoshida S, Ono M, Kuwano M, Nakamura Y, and Tokino T (1997). A
novel brain - specific p53 - target gene, BAI1, containing thrombospon-
din type 1 repeats inhibits experimental angiogenesis. Oncogene 15,
2145–50.
[17] Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T,
Nishimori H, Tamai K, Tokino T, Nakamura Y, and Taya Y (2000).
p53AIP1, a potential mediator of p53 -dependent apoptosis, and its
regulation by ser - 46 - phosphorylated p53. Cell 102, 849–62.
[18] Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A,
Ochiai K, Takagi T, and Nakamura Y (2000). Identification by cDNA
microarray of genes involved in ovarian carcinogenesis. Cancer Res
60, 5007–11.
[19] el -Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, and Vogelstein B
(1992). Definition of a consensus binding site for p53. Nat Genet 1,
45–49.
[20] Price DH (2000). P -TEFb, a cyclin - dependent kinase controlling
elongation by RNA polymerase II. Mol Cell Biol 20, 2629–34.
[21] Okamoto K, and Beach D (1994). Cyclin G is a transcriptional target of
the p53 tumor suppressor protein. EMBO J 13, 4816–22.
[22] Okamoto K, and Prives C (1999). A role of cyclin G in the process of
apoptosis. Oncogene 18, 4606–15.
274 Cyclin K Is a Target for p53 Mori et al.
Neoplasia . Vol. 4, No. 3, 2002
